Bo Wei Email & Phone Number

Rahway, New Jersey, Us

Rahway, New Jersey, Us

• Lead several in-house cross functional projects that evaluate various gene expression profiling and next generation sequencing (NGS) based diagnostic assays for the immuno-oncology clinical trials.• Work as exploratory biomarker lead for the development and evaluation of molecular biomarkers to predict clinical responses in the head and neck carcinoma indication for the KEYTRUDA studies.• Developed and validated the qPCR assay that was used to analyze the primary end point of the Phase II STOP CHAGS clinical trial.

Rahway, New Jersey, Us

• Developed and validated genotype-specific NGS assays to detect resistance associated substitutes for a Phase III HCV clinical trial conducted in China. Developed and validated a template-independent NGS assay for mixed HCV infection detection for a Phase III trial with subjects on opiate substitution therapy. Supported all HCV clinical studies through vendor evaluation and assay qualification.• Supported multiple clinical trials by analyzing samples collected for exploratory objectives with in-house developed custom NGS assays built on both Illumina and Ion Torrent platforms.• Evaluated and optimized DNA and RNA extraction methodologies and mRNA profiling technologies such as NanoString for formalin-fixed paraffin-embedded (FFPE) samples.

Rahway, New Jersey, Us

• Developed and validated TaqMan, SNaPshot, Sanger sequencing, and Luminex xMAP based SNP genotyping assays to analyze samples collected from various clinical studies.• Provided scientific expertise in assay design and validation, method troubleshooting, and technical oversight for CDL's outsourced nucleic acid-based clinical biomarker assays.• Participated in the later abandoned effort of establishing a CLIA certified clinical laboratory in CDL through developing and validating of genotyping assays for certificate of high complexity test, establishing SOPs and designing a Title 21 CFR Part 11 compliant database to track clinical specimens.• Led the effort of establishing the research capability for nucleic acid-based assays in CDL.

Seattle, Washington, Us

• Optimized sample collection procedure and RNA extraction method of plucked human scalp hair follicles and evaluated them as a surrogate tissue in measuring pharmacodynamics (PD) effects of chemo-therapeutic compounds such as AurA, Notch and Wee1 inhibitors in Phase I trials. Participated in PD biomarker discovery and assay validation efforts.• Developed an automated high-throughput method to isolate total RNA including miRNA from various tissue type samples with a 96-well plate-based platform. Evaluated and optimized technologies that enable gene expression profiling using whole blood RNA samples with little globin mRNA interference.• Collaborated with biostatisticians in establishing statistical algorithm and standardized programming tools for processing and analyzing RT-qPCR data. Designed and implemented a clinical sample tracking database to provide instructions and to record the results of pooling and splitting of atherosclerosis plaque samples for RNA, DNA, and protein analyses.

Us

• Developed and implemented cell-based assays to evaluate cellular absorption, cytotoxicity, and on-target efficacy of small molecule inhibitors of protein tyrosine phosphatase 1B (PTP-1B) to develop drugs for type 2 diabetes and obesity. Evaluated the pharmacokinetic properties of the inhibitors utilizing liquid chromatography-mass spectrometry (LC/MS).• Established the in-house qPCR facility. Designed and implemented qPCR assays for gene expression profiling. Categorized potential oncology targets in the PTP family through gene expression profiling and literature search. Evaluated potential oncology targets with cell-based assays utilizing RNAi technology. Assisted in generating a PTP knockout mouse model to evaluate its function in Toll-like receptor 4 mediated signal pathway.• Designed and maintained a comprehensive in-house database and utilized this database to search for novel PTPs. Co-discovered 17 dual specific phosphatases that were once granted patent status.• Core member of the company’s Protein Expression Team. Subcloned and expressed full-length cDNAs for the majority of human and mouse PTPs. Optimized experimental conditions and expression vector designs for large-scale purification of enzymatically active proteins.

Developed Differential Display PCR (DD-PCR) methods for animal aging studies. Utilized oxidatively stressed primary cell cultures and calorically restricted animal models to identify genes involved in aging. Implemented various gene expression analysis methods to confirm the data obtained through DD-PCR.

Chicago, Il, Us

Worked in the laboratory of Dr. Godfrey S. Getz, a recognized authority on atherosclerosis, to study the molecular mechanisms of the disease, including the relationship between dietary lipids and formation of lipoproteins and their consequent impact on atherosclerosis, and the role of the immune system in the evolution of atherosclerosis in murine models. Investigated the function of serum amyloid A (SAA), a major acute phase protein, through its association with HDL, in atherogenesis.

Master'S Degree, Cell And Molecular Biology

Associate'S Degree, It Applications Development

Bachelor'S Degree, Biology